Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STUART H COHEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1043290455
CMS profile
92012
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$12.70

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $12.70 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $12.70 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STUART H COHEN

NPI 1043290455 · CMS profile ID 92012

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043290455?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043290455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043290455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
STUART H COHEN, NPI 1043290455, CMS profile ID 92012, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1043290455?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $12.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $12.7003/04/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747614725 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $12.70 1
PY2021 $1,209.35 3
PY2023 $9,413.35 4
PY2024 $1,236.34 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,103.03 26
PY2024 Principal investigator $398,042.05 23
PY2023 Principal investigator $282,460.56 40
PY2022 Principal investigator $308,819.56 68
PY2021 Principal investigator $475,681.35 25
PY2020 Principal investigator $354,189.73 100
PY2019 Principal investigator $195,701.36 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $7,971.41 12/31/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 940392683
Principal investigator 1 Merck Sharp & Dohme LLC $10,396.58 12/31/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 940392725
Principal investigator 1 Merck Sharp & Dohme LLC $2,140.92 12/31/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 940393193
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 12/30/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964188487
Principal investigator 1 ABBVIE INC. $30,135.00 12/01/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)x2FPibrentasvir (PIB) No dispute reported 06/30/2026 890369473
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 11/30/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964188345
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,113.30 11/23/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964188311
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $2,376.90 11/16/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964188281
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 10/31/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964188181
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 09/30/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964188031
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,113.30 09/26/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187975
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $272.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187809
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $316.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187815
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $544.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187821
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $630.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187827
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $668.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187833
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $942.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187839
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,140.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187845
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,197.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187851
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $3,024.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187857
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $3,240.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187865
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $3,375.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187869
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $4,161.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187876
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $8,542.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187882
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $9,329.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187887
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $20,412.00 09/07/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187895
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 08/31/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187721
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,240.20 08/26/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187667
Principal investigator 1 PFIZER INC. $2,500.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965136963
Principal investigator 1 PFIZER INC. $350.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965136965
Principal investigator 1 PFIZER INC. $630.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965136973
Principal investigator 1 PFIZER INC. $1,200.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965136975
Principal investigator 1 PFIZER INC. $2,150.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965137023
Principal investigator 1 PFIZER INC. $2,709.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965137025
Principal investigator 1 PFIZER INC. $1,000.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965137027
Principal investigator 1 PFIZER INC. $1,000.00 08/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 2 OPENLABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APX001 IN THE TREATMENT OF PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPECIES OR RARE MOLDS No dispute reported 06/30/2026 965137035
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 07/30/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187589
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $6,633.00 07/22/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187531
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,600.00 07/20/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187501
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 06/30/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187443
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,063.80 06/27/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187383
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,312.20 06/01/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187303
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 05/31/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187255
Principal investigator 1 ABBVIE INC. $3,343.00 05/19/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)x2FPibrentasvir (PIB) No dispute reported 06/30/2026 890363689
Principal investigator 1 Gilead Sciences, Inc. $7,230.00 05/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation No dispute reported 06/30/2026 920357933
Principal investigator 1 PFIZER INC. $1,400.00 05/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949805939
Principal investigator 1 PFIZER INC. $18,060.00 05/05/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949809033
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,157.40 05/02/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964187177
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 04/29/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46,031.89 04/21/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938611505
Principal investigator 1 Merck Sharp & Dohme LLC $1,600.00 04/18/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 940393191
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 03/31/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964187029
Principal investigator 1 PFIZER INC. $2,000.00 03/31/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949808703
Principal investigator 1 PFIZER INC. $4,050.00 03/31/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949808897
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,312.20 03/25/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964186941
Principal investigator 1 PFIZER INC. $3,000.00 03/10/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949808751
Principal investigator 1 PFIZER INC. $750.00 03/10/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949808895
Principal investigator 1 PFIZER INC. $350.00 03/10/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949809003
Principal investigator 1 PFIZER INC. $1,500.00 03/10/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949809253
Principal investigator 1 PFIZER INC. $1,350.00 03/10/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949809255
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,447.36 03/09/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ENSOVIBEP (MP0420) IN AMBULATORY ADULT PATIENTS WITH SYMPTOMATIC COVID-19 No dispute reported 06/30/2026 910070278
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,674.90 03/04/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964186809
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 02/28/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964186755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,707.80 02/03/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938611497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,473.44 02/03/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938611499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,966.76 02/03/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938611501
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $45.00 01/31/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA DAVIS HEALTH SYSTEM
D-LIVR No dispute reported 06/30/2026 964186559
Principal investigator 1 EIGER BIOPHARMACEUTICALS, INC. $1,447.20 01/21/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
D-LIVR No dispute reported 06/30/2026 964186489